|
- LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC High-Risk CSCC
Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, as an adjuvant treatment for high-risk CSCC Review Important Safety Info Full Prescribing Information including Med Guide
- What is LIBTAYO® (cemiplimab-rwlc) | Advanced CSCC
LIBTAYO, an immunotherapy, may help with certain kinds of cancer LIBTAYO is a treatment that works by blocking cancer cells from binding with PD-1 This enables T cells to detect cancer cells and attack them LIBTAYO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work
- Treatment for Advanced CSCC | LIBTAYO® (cemiplimab-rwlc)
Learn about LIBTAYO® (cemiplimab-rwlc) for the treatment of advanced CSCC Review Important Safety Info Full Prescribing Information including Med Guide
- LIBTAYO Full Prescribing Information
LIBTAYO as a single agent is indicated for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test [see Dosage and Administration (2 1)], with no EGFR, ALK or ROS1 aberrations, and is:
- Taking LIBTAYO® (cemiplimab-rwlc) | Advanced BCC
Patient examples from LIBTAYO trials Below are examples of 3 patients with locally advanced BCC previously treated with an HHI, who saw tumors shrink (partial response) with treatment In this trial, 25% (21 out of 84) patients had a partial response with LIBTAYO Individual patient responses may vary Patient example 1 Pictured below is a facial lesion of a 77-year-old female patient The
- What is LIBTAYO® (cemiplimab-rwlc) | Advanced BCC
LIBTAYO is a prescription medicine used to treat adults with a type of skin cancer called basal cell carcinoma (BCC) that: Cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC), and you have previously received treatment with a hedgehog pathway inhibitor (HHI), or you cannot receive treatment with a HHI
- Patient Stories in Advanced CSCC | LIBTAYO® (cemiplimab-rwlc)
Meaningful stories Meaningful hope It can be helpful and inspiring to hear the experiences of people living with advanced CSCC and their treatment with LIBTAYO LIBTAYO is a prescription medicine used to treat adults with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) LIBTAYO may be used to treat CSCC that has spread or cannot be cured by surgery or radiation
- Patient Resources for LIBTAYO® (cemiplimab-rwlc) | Advanced NSCLC
LIBTAYO tools for patients caregivers LIBTAYO resources Get more information about LIBTAYO and how it may be an appropriate treatment option for your advanced NSCLC
|
|
|